After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
XLO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Xilio Therapeutics Inc is $43.59M. A total of 0.64 million shares were traded on the day, compared to an average of 565.81K shares.
In the most recent transaction, Shannon James Samuel bought 45,000 shares of XLO for 0.69 per share on Jun 16 ’25. After the transaction, the Director now owns 45,000 company shares. In a previous transaction on Jun 17 ’25, Shannon James Samuel bought 25,000 shares at 0.69 per share. XLO shares that Director owns now total 70,000.
Among the insiders who bought shares, Russo Rene acquired of 36,289 shares on Jun 16 ’25 at a per-share price of $0.68. This resulted in the PRESIDENT AND CEO holding 281,172 shares of XLO after the transaction. In another insider transaction, Frankenfield Christopher James sold 6,954 shares at $0.98 per share on Jan 02 ’25. Company shares held by the Chief Financial Officer now total 12,421.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, XLO has a high of $1.70 and a low of $0.62.
As of this writing, XLO has an earnings estimate of -$0.03 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of $0.02 per share and a lower estimate of -$0.08. The company reported an EPS of -$0.22 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. XLO’s latest balance sheet shows that the firm has $198.05M in Cash & Short Term Investments as of fiscal 2021. There were $20.54M in debt and $12.78M in liabilities at the time. Its Book Value Per Share was $0.14, while its Total Shareholder’s Equity was $185.43M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XLO is Buy with a score of 4.33.
